Table 1 Characteristics of the 17 RCTs included in the meta-analysis of ICSs and risk of URTI
Study | Duration (months) | Mean Age (years) | FEV1 (%predicted) | Male (%) | Interventions | NO. of URTI/Total |
|---|---|---|---|---|---|---|
Mahler et al. [13] | 5.5 | 63.5 | 40.8 | 66.0 | T:FP 500 μg bid or FSC (S 50 μg /FP 500 μg) bid | T:84/342 |
C: Placebo or S 50 μg bid | C: 56/349 | |||||
Hanania et al. [22] | 5.5 | 63.8 | 41.8 | 63.2 | T:FP 250 μg bid or FSC (S 50 μg /FP 250 μg) bid | T:40/361 |
C: Placebo or S 50 μg bid | C: 42/362 | |||||
Calverley et al. [11] | 36 | 65.0 | 44.0 | 75.5 | T:FP 500 μg bid or FSC (S 50 μg /FP 500 μg) bid | T:309/3098 |
C: Placebo or S 50 μg bid | C: 277/3086 | |||||
Zheng et al. [23] | 5.5 | 66.2 | 47.0 | 89.2 | T:FSC (S 50 μg /FP 500 μg) bid | T:32/297 |
C: Placebo | C: 14/148 | |||||
Ferguson et al. [24] | 12 | 65.0 | 32.8 | 55.0 | T:FP 250 μg bid | T:31/394 |
C: S 50 μg bid | C: 31/388 | |||||
Calverley et al. [25] | 12 | 65.1 | NR | 68.3 | T: MF 800 μg qd or MF 400 μg bid | T:164/616 |
C: Placebo | C: 71/295 | |||||
Anzueto et al. [26] | 12 | 65.4 | 34 | 54.0 | T:FSC (S 50 μg /FP 500 μg) bid | T:41/394 |
C: Placebo | C: 30/403 | |||||
Calverley et al. [27] | 11 | 63.6 | 42.2 | 80.7 | T:BDP/FM 200/12 μg bid or BUD/FM 400/12 μg bid | T:3/479 |
C: FM 12 μg bid | C: 5/239 | |||||
Tashkin et al. [30] | 6 | 59.8 | NR | 77.5 | T: MF/FM 200/10 μg bid or MF/FM 400/10 μg bid or MF 400 μg bid | T:19/634 |
C: Placebo or FM 10 μg bid | C:13/421 | |||||
Tashkin et al. [16] | 12 | 59.7 | 39.1 | 76.0 | T: MF/FM 200/10 μg bid or MF/FM 400/10 μg bid or MF 400 μg bid | T:58/1351 |
C: Placebo or FM 10 μg bid | C: 39/900 | |||||
Doherty et al. [29] | 6 | 59.6 | 38.6 | 75.2 | T: MF/FM 200/10 μg bid or MF/FM 400/10 μg bid or MF 400 μg bid | T:39/717 |
C: Placebo or FM 10 μg bid | C: 26/479 | |||||
Sharafkhaneh et al. [12] | 12 | 63.0 | 37.7 | 62.0 | T:BUD/FM 320/9 μg bid or BUD/FM 160/9 μg bid | T:90/815 |
C: FM 9 μg bid | C: 39/403 | |||||
Boscia et al. [28] | 1 | 57.9 | 49.8 | 46.3 | T:FF/VI 50/25 μg qd or FF/VI 100/25 μg qd or FF/VI 200/25 μg qd | T:2/98 |
C: Placebo | C: 1/51 | |||||
Vogelmeier et al. [15] | 6 | 63.3 | 60.3 | 70.9 | T: FSC (S 50 μg /FP 500 μg) bid | T:2/264 |
C: QVA149 110/50 μg qd | C: 7/258 | |||||
Kerwin et al. [14] | 5.5 | 62.5 | 48.3 | 66.6 | T:FF/VI 50/25 μg qd or FF/VI 100/25 μg qd or FF 100 μg qd | T:50/618 |
C: Placebo or VI 25 μg qd | C: 19/412 | |||||
Martinez et al. [17] | 5.5 | 61.5 | 47.9 | 72.3 | T:FF/VI 100/25 μg qd or FF/VI 200/25 μg qd or FF 100 μg qd or FF 200 μg qd | T:23/816 |
C: Placebo or VI 25 μg qd | C: 14/408 | |||||
Huang et al. [31] | 2.8 | 64.1 | NR | 86.4 | T: BUD/FM 320/9 μg bid, I 40 μg qid and T 100 mg bid | T:4/293 |
C:I 40 μg qid and Th 100 mg bid | C: 2/289 |